|
|
|
51-200 employees
View all
|
|
Industrie pharmaceutique
|
|
2310 Alfred-Nobel Blvd.,Montreal,Quebec,CA
|
|
Theratechnologies (TSX: TH) is a specialty pharmaceutical Corporation that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. Theratechnologies' strategy is to leverage its expertise in the field of metabolism and GRF peptides to address serious health disorders while remaining actively involved in the commercialization of its future products. Its first product, EGRIFTA™ (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA™ is the only approved therapy for the reduction of excess abdominal fat in people living with HIV.
|
Theratechnologies Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
66.67%
|
The widely used Theratechnologies email format is {f}{last} (e.g. [email protected]) with 66.67% adoption across the company.
To contact Theratechnologies customer service number in your country click here to find.
Luc Tanguay is the CEO of Theratechnologies.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.